In this interview, Sienna’s CEO Matthew Hoskin speaks to FNN’s Jessica Amir about the Johns Hopkins clinical study results, and the company’s progress on additional applications and geographical expansion for the in-vitro diagnostic (IVD) test for hTERT.
Comment